Drug Discovery Today staff taking short break over Christmas and New Year holiday period
25 December, 2009
AstraZeneca and the University of Virginia in Charlottesville recently announced that they have entered into a strategic research collaboration to enhance the development of new treatments primarily for coronary artery disease with a secondary focus on peripheral vascular disease.
24 December, 2009
Merck & Co. recently announced the appointment of Dr Michael Rosenblatt as Executive Vice President and Chief Medical Officer. Dr Rosenblatt will be Merck's primary voice to the global medical community.
23 December, 2009
Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases ulcerative colitis and Crohn's disease, say scientists.
22 December, 2009
The Children’s Hospital research team believes the discovery will lead to more accurate and efficient diagnosis.
17 December, 2009
Cequent Pharmaceuticals, a biopharmaceutical company that develops products to deliver RNAi-based treatments for the prevention and treatment of human disease, announced recently that the FDA Center for Biologics Evaluation and Research has approved Cequent’s first investigational new drug (IND) application.
16 December, 2009
ThromboGenics NV announced recently that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) age-related macular degeneration.
15 December, 2009
Light Sciences Oncology is anticipating significant short-term progress in the company’s multi-front development of Aptocine™ (talaporfin sodium), a novel treatment for solid tumors and benign neoplasms, including BPH.
14 December, 2009
The Cambridge Crystallographic Data Centre has proudly announced the archiving of the 500,000th small-molecule crystal structure to the Cambridge Structural Database.
10 December, 2009
The National Cancer Institute has entered into a research and development collaboration with Mayo Clinic to expand on recent research discoveries at Mayo, where researchers have demonstrated the importance of a key protein involved in pancreatic and lung cancer.
09 December, 2009
An antibiotic that binds to a well-established target in a novel and unexpected way could be the inspiration for designing new, more potent antibiotic drugs.
04 December, 2009
Domainex Ltd. has released the next generation of its LeadBuilder virtual screening technology. LeadBuilder is the proprietary lead generation platform developed by Domainex to provide unusually rapid and cost-effective access to high-quality small-molecule drug leads, particularly against novel or difficult target proteins.
03 December, 2009
EMBL and CRG scientists reveal what a self-sufficient cell can’t do without.
03 December, 2009
Research efforts to help the world's ageing population live longer, healthier lives have been given a major boost with the announcement of six new transatlantic research projects that aim to understanding the biology of the ageing process.
02 December, 2009
UK-based Synexus recruited in excess of 2000 children aged between five and ten weeks of age over the course of three months, making Synexus the largest single source of subjects for a Phase III trial that investigated a paediatric vaccine against rotavirus and involved more than 3167 children across South Africa.
01 December, 2009